HIV can develop resistance to lenacapavir, but at a cost to the virus
Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game…
Greed Is a Hell of a Drug
On Sept. 24, the California-based multinational corporation Gilead Sciences announced it would lower the price of lenacapavir — a…
HIV can end now: Groundbreaking drug to be rolled out from 2027 at an affordable price (know how much it will cost)
Light at the end of the tunnel, at last!It seems HIV is finally on its way to being…
Expanding Access to HIV Prevention Tool for Millions
New partnership will join others to expand access to generic lenacapavir for millions more people at risk…